

House _____ Amendment NO. _____

Offered By _____

1 AMEND Senate Bill No. 561, Page 1, in the Title, Line 3, by deleting the words "the county in
2 which certain offenses are prosecuted" and inserting in lieu thereof the words "public safety"; and
3

4 Further amend said bill and page, Section A, Line 2, by inserting immediately after all of said line
5 the following:
6

7 "43.545. The state highway patrol shall include [in its voluntary system of reporting for
8 compilation in the "Crime in Missouri"] all reported incidents of domestic violence, as defined in
9 section 455.010, whether or not an arrest is made, in its system of reporting for compilation in the
10 annual crime report published under section 43.505. All incidents shall be reported on forms
11 provided by the highway patrol and in a manner prescribed by the patrol.

12 195.010. The following words and phrases as used in this chapter and chapter 579, unless the
13 context otherwise requires, mean:

14 (1)"Addict", a person who habitually uses one or more controlled substances to such an
15 extent as to create a tolerance for such drugs, and who does not have a medical need for such drugs,
16 or who is so far addicted to the use of such drugs as to have lost the power of self-control with
17 reference to his or her addiction;

18 (2)"Administer", to apply a controlled substance, whether by injection, inhalation, ingestion,
19 or any other means, directly to the body of a patient or research subject by:

20 (a)A practitioner (or, in his or her presence, by his or her authorized agent); or

21 (b)The patient or research subject at the direction and in the presence of the practitioner;

22 (3)"Agent", an authorized person who acts on behalf of or at the direction of a manufacturer,
23 distributor, or dispenser. The term does not include a common or contract carrier, public
24 warehouseman, or employee of the carrier or warehouseman while acting in the usual and lawful
25 course of the carrier's or warehouseman's business;

26 (4)"Attorney for the state", any prosecuting attorney, circuit attorney, or attorney general
27 authorized to investigate, commence and prosecute an action under this chapter;

28 (5)"Controlled substance", a drug, substance, or immediate precursor in Schedules I through
29 V listed in this chapter. The term includes an altered state of a drug or substance listed in Schedules I
30 through V absorbed into the human body;

31 (6)"Controlled substance analogue", a substance the chemical structure of which is
32 substantially similar to the chemical structure of a controlled substance in Schedule I or II and:

33 (a)Which has a stimulant, depressant, or hallucinogenic effect on the central nervous system
34 substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous
35 system of a controlled substance included in Schedule I or II; or

36 (b)With respect to a particular individual, which that individual represents or intends to have

Action Taken _____ Date _____

Action Taken _____ Date _____

1 a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar
2 to the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled
3 substance included in Schedule I or II. The term does not include a controlled substance; any
4 substance for which there is an approved new drug application; any substance for which an
5 exemption is in effect for investigational use, for a particular person, under Section 505 of the
6 federal Food, Drug and Cosmetic Act (21 U.S.C. Section 355) to the extent conduct with respect to
7 the substance is pursuant to the exemption; or any substance to the extent not intended for human
8 consumption before such an exemption takes effect with respect to the substance;

9 (7)"Counterfeit substance", a controlled substance which, or the container or labeling of
10 which, without authorization, bears the trademark, trade name, or other identifying mark, imprint,
11 number or device, or any likeness thereof, of a manufacturer, distributor, or dispenser other than the
12 person who in fact manufactured, distributed, or dispensed the substance;

13 (8)"Deliver" or "delivery", the actual, constructive, or attempted transfer from one person to
14 another of drug paraphernalia or of a controlled substance, or an imitation controlled substance,
15 whether or not there is an agency relationship, and includes a sale;

16 (9)"Dentist", a person authorized by law to practice dentistry in this state;

17 (10)"Depressant or stimulant substance":

18 (a)A drug containing any quantity of barbituric acid or any of the salts of barbituric acid or
19 any derivative of barbituric acid which has been designated by the United States Secretary of Health
20 and Human Services as habit forming under 21 U.S.C. Section 352(d);

21 (b)A drug containing any quantity of:

22 a. Amphetamine or any of its isomers;

23 b. Any salt of amphetamine or any salt of an isomer of amphetamine; or

24 c. Any substance the United States Attorney General, after investigation, has found to be, and
25 by regulation designated as, habit forming because of its stimulant effect on the central nervous
26 system;

27 (c) Lysergic acid diethylamide; or

28 (d) Any drug containing any quantity of a substance that the United States Attorney General,
29 after investigation, has found to have, and by regulation designated as having, a potential for abuse
30 because of its depressant or stimulant effect on the central nervous system or its hallucinogenic
31 effect;

32 (11)"Dispense", to deliver a narcotic or controlled dangerous drug to an ultimate user or
33 research subject by or pursuant to the lawful order of a practitioner including the prescribing,
34 administering, packaging, labeling, or compounding necessary to prepare the substance for such
35 delivery. "Dispenser" means a practitioner who dispenses;

36 (12)"Distribute", to deliver other than by administering or dispensing a controlled substance;

37 (13)"Distributor", a person who distributes;

38 (14)"Drug":

39 (a) Substances recognized as drugs in the official United States Pharmacopoeia, Official
40 Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
41 supplement to any of them;

42 (b) Substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of
43 disease in humans or animals;

44 (c) Substances, other than food, intended to affect the structure or any function of the body of
45 humans or animals; and

46 (d) Substances intended for use as a component of any article specified in this subdivision. It
47 does not include devices or their components, parts or accessories;

48 (15)"Drug-dependent person", a person who is using a controlled substance and who is in a

1 state of psychic or physical dependence, or both, arising from the use of such substance on a
2 continuous basis. Drug dependence is characterized by behavioral and other responses which include
3 a strong compulsion to take the substance on a continuous basis in order to experience its psychic
4 effects or to avoid the discomfort caused by its absence;

5 (16) "Drug enforcement agency", the Drug Enforcement Administration in the United States
6 Department of Justice, or its successor agency;

7 (17) "Drug paraphernalia", all equipment, products, substances and materials of any kind
8 which are used, intended for use, or designed for use, in planting, propagating, cultivating, growing,
9 harvesting, manufacturing, compounding, converting, producing, processing, preparing, storing,
10 containing, concealing, injecting, ingesting, inhaling, or otherwise introducing into the human body
11 a controlled substance or an imitation controlled substance in violation of this chapter or chapter
12 579. It includes, but is not limited to:

13 (a) Kits used, intended for use, or designed for use in planting, propagating, cultivating,
14 growing or harvesting of any species of plant which is a controlled substance or from which a
15 controlled substance can be derived;

16 (b) Kits used, intended for use, or designed for use in manufacturing, compounding,
17 converting, producing, processing, or preparing controlled substances or imitation controlled
18 substances;

19 (c) Isomerization devices used, intended for use, or designed for use in increasing the potency
20 of any species of plant which is a controlled substance or an imitation controlled substance;

21 (d) Testing equipment used, intended for use, or designed for use in identifying, or in
22 analyzing the strength, effectiveness or purity of controlled substances or imitation controlled
23 substances;

24 (e) Scales and balances used, intended for use, or designed for use in weighing or measuring
25 controlled substances or imitation controlled substances;

26 (f) Dilutents and adulterants, such as quinine hydrochloride, mannitol, mannite, dextrose and
27 lactose, used, intended for use, or designed for use in cutting controlled substances or imitation
28 controlled substances;

29 (g) Separation gins and sifters used, intended for use, or designed for use in removing twigs
30 and seeds from, or in otherwise cleaning or refining, marijuana;

31 (h) Blenders, bowls, containers, spoons and mixing devices used, intended for use, or
32 designed for use in compounding controlled substances or imitation controlled substances;

33 (i) Capsules, balloons, envelopes and other containers used, intended for use, or designed for
34 use in packaging small quantities of controlled substances or imitation controlled substances;

35 (j) Containers and other objects used, intended for use, or designed for use in storing or
36 concealing controlled substances or imitation controlled substances;

37 (k) Hypodermic syringes, needles and other objects used, intended for use, or designed for use
38 in parenterally injecting controlled substances or imitation controlled substances into the human
39 body;

40 (l) Objects used, intended for use, or designed for use in ingesting, inhaling, or otherwise
41 introducing marijuana, cocaine, hashish, or hashish oil into the human body, such as:

42 a. Metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes with or without screens,
43 permanent screens, hashish heads, or punctured metal bowls;

44 b. Water pipes;

45 c. Carburetion tubes and devices;

46 d. Smoking and carburetion masks;

47 e. Roach clips meaning objects used to hold burning material, such as a marijuana cigarette,
48 that has become too small or too short to be held in the hand;

- 1 f. Miniature cocaine spoons and cocaine vials;
- 2 g. Chamber pipes;
- 3 h. Carburetor pipes;
- 4 i. Electric pipes;
- 5 j. Air-driven pipes;
- 6 k. Chillums;
- 7 l. Bongs;
- 8 m. Ice pipes or chillers;
- 9 (m) Substances used, intended for use, or designed for use in the manufacture of a controlled
- 10 substance;
- 11 In determining whether an object, product, substance or material is drug paraphernalia, a court or
- 12 other authority should consider, in addition to all other logically relevant factors, the following:
- 13 a. Statements by an owner or by anyone in control of the object concerning its use;
- 14 b. Prior convictions, if any, of an owner, or of anyone in control of the object, under any state
- 15 or federal law relating to any controlled substance or imitation controlled substance;
- 16 c. The proximity of the object, in time and space, to a direct violation of this chapter or
- 17 chapter 579;
- 18 d. The proximity of the object to controlled substances or imitation controlled substances;
- 19 e. The existence of any residue of controlled substances or imitation controlled substances on
- 20 the object;
- 21 f. Direct or circumstantial evidence of the intent of an owner, or of anyone in control of the
- 22 object, to deliver it to persons who he or she knows, or should reasonably know, intend to use the
- 23 object to facilitate a violation of this chapter or chapter 579; the innocence of an owner, or of anyone
- 24 in control of the object, as to direct violation of this chapter or chapter 579 shall not prevent a finding
- 25 that the object is intended for use, or designed for use as drug paraphernalia;
- 26 g. Instructions, oral or written, provided with the object concerning its use;
- 27 h. Descriptive materials accompanying the object which explain or depict its use;
- 28 i. National or local advertising concerning its use;
- 29 j. The manner in which the object is displayed for sale;
- 30 k. Whether the owner, or anyone in control of the object, is a legitimate supplier of like or
- 31 related items to the community, such as a licensed distributor or dealer of tobacco products;
- 32 l. Direct or circumstantial evidence of the ratio of sales of the object to the total sales of the
- 33 business enterprise;
- 34 m. The existence and scope of legitimate uses for the object in the community;
- 35 n. Expert testimony concerning its use;
- 36 o. The quantity, form or packaging of the product, substance or material in relation to the
- 37 quantity, form or packaging associated with any legitimate use for the product, substance or material;
- 38 (18) "Federal narcotic laws", the laws of the United States relating to controlled substances;
- 39 (19) "Hospital", a place devoted primarily to the maintenance and operation of facilities for
- 40 the diagnosis, treatment or care, for not less than twenty-four hours in any week, of three or more
- 41 nonrelated individuals suffering from illness, disease, injury, deformity or other abnormal physical
- 42 conditions; or a place devoted primarily to provide, for not less than twenty-four consecutive hours
- 43 in any week, medical or nursing care for three or more nonrelated individuals. The term "hospital"
- 44 does not include convalescent, nursing, shelter or boarding homes as defined in chapter 198;
- 45 (20) "Immediate precursor", a substance which:
- 46 (a) The state department of health and senior services has found to be and by rule designates
- 47 as being the principal compound commonly used or produced primarily for use in the manufacture of
- 48 a controlled substance;

1 (b)Is an immediate chemical intermediary used or likely to be used in the manufacture of a
2 controlled substance; and

3 (c)The control of which is necessary to prevent, curtail or limit the manufacture of the
4 controlled substance;

5 (21)"Imitation controlled substance", a substance that is not a controlled substance, which by
6 dosage unit appearance (including color, shape, size and markings), or by representations made,
7 would lead a reasonable person to believe that the substance is a controlled substance. In determining
8 whether the substance is an imitation controlled substance the court or authority concerned should
9 consider, in addition to all other logically relevant factors, the following:

10 (a)Whether the substance was approved by the federal Food and Drug Administration for
11 over-the-counter (nonprescription or nonlegend) sales and was sold in the federal Food and Drug
12 Administration approved package, with the federal Food and Drug Administration approved labeling
13 information;

14 (b)Statements made by an owner or by anyone else in control of the substance concerning the
15 nature of the substance, or its use or effect;

16 (c)Whether the substance is packaged in a manner normally used for illicit controlled
17 substances;

18 (d)Prior convictions, if any, of an owner, or anyone in control of the object, under state or
19 federal law related to controlled substances or fraud;

20 (e)The proximity of the substances to controlled substances;

21 (f)Whether the consideration tendered in exchange for the noncontrolled substance
22 substantially exceeds the reasonable value of the substance considering the actual chemical
23 composition of the substance and, where applicable, the price at which over-the-counter substances
24 of like chemical composition sell. An imitation controlled substance does not include a placebo or
25 registered investigational drug either of which was manufactured, distributed, possessed or delivered
26 in the ordinary course of professional practice or research;

27 (22)"Laboratory", a laboratory approved by the department of health and senior services as
28 proper to be entrusted with the custody of controlled substances but does not include a pharmacist
29 who compounds controlled substances to be sold or dispensed on prescriptions;

30 (23)"Manufacture", the production, preparation, propagation, compounding or processing of
31 drug paraphernalia or of a controlled substance, or an imitation controlled substance, either directly
32 or by extraction from substances of natural origin, or independently by means of chemical synthesis,
33 or by a combination of extraction and chemical synthesis, and includes any packaging or
34 repackaging of the substance or labeling or relabeling of its container. This term does not include the
35 preparation or compounding of a controlled substance or an imitation controlled substance or the
36 preparation, compounding, packaging or labeling of a narcotic or dangerous drug;

37 (a)By a practitioner as an incident to his or her administering or dispensing of a controlled
38 substance or an imitation controlled substance in the course of his or her professional practice, or

39 (b)By a practitioner or his or her authorized agent under his or her supervision, for the
40 purpose of, or as an incident to, research, teaching or chemical analysis and not for sale;

41 (24)"Marijuana", all parts of the plant genus Cannabis in any species or form thereof,
42 including, but not limited to Cannabis Sativa L., Cannabis Indica, Cannabis Americana, Cannabis
43 Ruderalis, and Cannabis Gigantea, whether growing or not, the seeds thereof, the resin extracted
44 from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or
45 preparation of the plant, its seeds or resin. It does not include the mature stalks of the plant, fiber
46 produced from the stalks, oil or cake made from the seeds of the plant, any other compound,
47 manufacture, salt, derivative, mixture or preparation of the mature stalks (except the resin extracted
48 therefrom), fiber, oil or cake, or the sterilized seed of the plant which is incapable of germination;

1 (25)"Methamphetamine precursor drug", any drug containing ephedrine, pseudoephedrine,
2 phenylpropanolamine, or any of their salts, optical isomers, or salts of optical isomers;

3 (26)"Narcotic drug", any of the following, whether produced directly or indirectly by
4 extraction from substances of vegetable origin, or independently by means of chemical synthesis, or
5 by a combination of extraction and chemical analysis:

6 (a)Opium, opiate, and any derivative, of opium or opiate, including their isomers, esters,
7 ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters,
8 ethers, and salts is possible within the specific chemical designation. The term does not include the
9 isoquinoline alkaloids of opium;

10 (b)Coca leaves, but not including extracts of coca leaves from which cocaine, ecgonine, and
11 derivatives of ecgonine or their salts have been removed;

12 (c)Cocaine or any salt, isomer, or salt of isomer thereof;

13 (d)Ecgonine, or any derivative, salt, isomer, or salt of isomer thereof;

14 (e)Any compound, mixture, or preparation containing any quantity of any substance referred
15 to in paragraphs (a) to (d) of this subdivision;

16 (27)"Official written order", an order written on a form provided for that purpose by the
17 United States Commissioner of Narcotics, under any laws of the United States making provision
18 therefor, if such order forms are authorized and required by federal law, and if no such order form is
19 provided, then on an official form provided for that purpose by the department of health and senior
20 services;

21 (28)"Opiate", any substance having an addiction-forming or addiction-sustaining liability
22 similar to morphine or being capable of conversion into a drug having addiction-forming or
23 addiction-sustaining liability. The term includes its racemic and levorotatory forms. It does not
24 include, unless specifically controlled under section 195.017, the dextrorotatory isomer of
25 3-methoxy-n-methyl-morphinan and its salts (dextromethorphan);

26 (29)"Opium poppy", the plant of the species *Papaver somniferum* L., except its seeds;

27 (30)"Over-the-counter sale", a retail sale licensed pursuant to chapter 144 of a drug other than
28 a controlled substance;

29 (31)"Person", an individual, corporation, government or governmental subdivision or agency,
30 business trust, estate, trust, partnership, joint venture, association, or any other legal or commercial
31 entity;

32 (32)"Pharmacist", a licensed pharmacist as defined by the laws of this state, and where the
33 context so requires, the owner of a store or other place of business where controlled substances are
34 compounded or dispensed by a licensed pharmacist; but nothing in this chapter shall be construed as
35 conferring on a person who is not registered nor licensed as a pharmacist any authority, right or
36 privilege that is not granted to him by the pharmacy laws of this state;

37 (33)"Poppy straw", all parts, except the seeds, of the opium poppy, after mowing;

38 (34)"Possessed" or "possessing a controlled substance", a person, with the knowledge of the
39 presence and nature of a substance, has actual or constructive possession of the substance. A person
40 has actual possession if he has the substance on his or her person or within easy reach and convenient
41 control. A person who, although not in actual possession, has the power and the intention at a given
42 time to exercise dominion or control over the substance either directly or through another person or
43 persons is in constructive possession of it. Possession may also be sole or joint. If one person alone
44 has possession of a substance possession is sole. If two or more persons share possession of a
45 substance, possession is joint;

46 (35)"Practitioner", a physician, dentist, optometrist, podiatrist, veterinarian, scientific
47 investigator, pharmacy, hospital or other person licensed, registered or otherwise permitted by this
48 state to distribute, dispense, conduct research with respect to or administer or to use in teaching or

1 chemical analysis, a controlled substance in the course of professional practice or research in this
 2 state, or a pharmacy, hospital or other institution licensed, registered, or otherwise permitted to
 3 distribute, dispense, conduct research with respect to or administer a controlled substance in the
 4 course of professional practice or research;

5 (36)"Production", includes the manufacture, planting, cultivation, growing, or harvesting of
 6 drug paraphernalia or of a controlled substance or an imitation controlled substance;

7 (37)"Registry number", the number assigned to each person registered under the federal
 8 controlled substances laws;

9 (38)"Sale", includes barter, exchange, or gift, or offer therefor, and each such transaction
 10 made by any person, whether as principal, proprietor, agent, servant or employee;

11 (39)"State" when applied to a part of the United States, includes any state, district,
 12 commonwealth, territory, insular possession thereof, and any area subject to the legal authority of the
 13 United States of America;

14 (40)"Synthetic cannabinoid"[.] includes unless specifically excepted or unless listed in
 15 another schedule, any natural or synthetic material, compound, mixture, or preparation that contains
 16 any quantity of a substance that is a cannabinoid receptor agonist, including but not limited to any
 17 substance listed in paragraph (11) of subdivision (4) of subsection 2 of section 195.017 and any
 18 analogues; homologues; isomers, whether optical, positional, or geometric; esters; ethers; salts; and
 19 salts of isomers, esters, and ethers, whenever the existence of the isomers, esters, ethers, or salts is
 20 possible within the specific chemical designation, however, it shall not include any approved
 21 pharmaceutical authorized by the United States Food and Drug Administration;

22 (41)"Ultimate user", a person who lawfully possesses a controlled substance or an imitation
 23 controlled substance for his or her own use or for the use of a member of his or her household or
 24 immediate family, regardless of whether they live in the same household, or for administering to an
 25 animal owned by him or by a member of his or her household. For purposes of this section, the
 26 phrase "immediate family" means a husband, wife, parent, child, sibling, stepparent, stepchild,
 27 stepbrother, stepsister, grandparent, or grandchild;

28 (42)"Wholesaler", a person who supplies drug paraphernalia or controlled substances or
 29 imitation controlled substances that he himself has not produced or prepared, on official written
 30 orders, but not on prescriptions.

31 195.010. The following words and phrases as used in sections 195.005 to 195.425, unless the
 32 context otherwise requires, mean:

33 (1)"Addict", a person who habitually uses one or more controlled substances to such an
 34 extent as to create a tolerance for such drugs, and who does not have a medical need for such drugs,
 35 or who is so far addicted to the use of such drugs as to have lost the power of self-control with
 36 reference to his addiction;

37 (2)"Administer", to apply a controlled substance, whether by injection, inhalation, ingestion,
 38 or any other means, directly to the body of a patient or research subject by:

39 (a) A practitioner (or, in his presence, by his authorized agent); or

40 (b) The patient or research subject at the direction and in the presence of the practitioner;

41 (3)"Agent", an authorized person who acts on behalf of or at the direction of a manufacturer,
 42 distributor, or dispenser. The term does not include a common or contract carrier, public
 43 warehouseman, or employee of the carrier or warehouseman while acting in the usual and lawful
 44 course of the carrier's or warehouseman's business;

45 (4)"Attorney for the state", any prosecuting attorney, circuit attorney, or attorney general
 46 authorized to investigate, commence and prosecute an action under sections 195.005 to 195.425;

47 (5)"Controlled substance", a drug, substance, or immediate precursor in Schedules I through
 48 V listed in sections 195.005 to 195.425. The term includes an altered state of a drug or substance

1 listed in Schedules I through V absorbed into the human body;

2 (6)"Controlled substance analogue", a substance the chemical structure of which is
3 substantially similar to the chemical structure of a controlled substance in Schedule I or II and:

4 (a)Which has a stimulant, depressant, or hallucinogenic effect on the central nervous system
5 substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous
6 system of a controlled substance included in Schedule I or II; or

7 (b)With respect to a particular individual, which that individual represents or intends to have
8 a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar
9 to the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled
10 substance included in Schedule I or II. The term does not include a controlled substance; any
11 substance for which there is an approved new drug application; any substance for which an
12 exemption is in effect for investigational use, for a particular person, under Section 505 of the
13 federal Food, Drug and Cosmetic Act (21 U.S.C. 355) to the extent conduct with respect to the
14 substance is pursuant to the exemption; or any substance to the extent not intended for human
15 consumption before such an exemption takes effect with respect to the substance;

16 (7)"Counterfeit substance", a controlled substance which, or the container or labeling of
17 which, without authorization, bears the trademark, trade name, or other identifying mark, imprint,
18 number or device, or any likeness thereof, of a manufacturer, distributor, or dispenser other than the
19 person who in fact manufactured, distributed, or dispensed the substance;

20 (8)"Deliver" or "delivery", the actual, constructive, or attempted transfer from one person to
21 another of drug paraphernalia or of a controlled substance, or an imitation controlled substance,
22 whether or not there is an agency relationship, and includes a sale;

23 (9)"Dentist", a person authorized by law to practice dentistry in this state;

24 (10)"Depressant or stimulant substance":

25 (a)A drug containing any quantity of barbituric acid or any of the salts of barbituric acid or
26 any derivative of barbituric acid which has been designated by the United States Secretary of Health
27 and Human Services as habit forming under 21 U.S.C. 352(d);

28 (b)A drug containing any quantity of:

29 a. Amphetamine or any of its isomers;

30 b. Any salt of amphetamine or any salt of an isomer of amphetamine; or

31 c. Any substance the United States Attorney General, after investigation, has found to be, and
32 by regulation designated as, habit forming because of its stimulant effect on the central nervous
33 system;

34 (c) Lysergic acid diethylamide; or

35 (d) Any drug containing any quantity of a substance that the United States Attorney General,
36 after investigation, has found to have, and by regulation designated as having, a potential for abuse
37 because of its depressant or stimulant effect on the central nervous system or its hallucinogenic
38 effect;

39 (11)"Dispense", to deliver a narcotic or controlled dangerous drug to an ultimate user or
40 research subject by or pursuant to the lawful order of a practitioner including the prescribing,
41 administering, packaging, labeling, or compounding necessary to prepare the substance for such
42 delivery. "Dispenser" means a practitioner who dispenses;

43 (12)"Distribute", to deliver other than by administering or dispensing a controlled substance;

44 (13)"Distributor", a person who distributes;

45 (14)"Drug":

46 (a) Substances recognized as drugs in the official United States Pharmacopoeia, Official
47 Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
48 supplement to any of them;

1 (b)Substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of
2 disease in humans or animals;

3 (c)Substances, other than food, intended to affect the structure or any function of the body of
4 humans or animals; and

5 (d)Substances intended for use as a component of any article specified in this subdivision.It
6 does not include devices or their components, parts or accessories;

7 (15)"Drug-dependent person", a person who is using a controlled substance and who is in a
8 state of psychic or physical dependence, or both, arising from the use of such substance on a
9 continuous basis.Drug dependence is characterized by behavioral and other responses which include
10 a strong compulsion to take the substance on a continuous basis in order to experience its psychic
11 effects or to avoid the discomfort caused by its absence;

12 (16)"Drug enforcement agency", the Drug Enforcement Administration in the United States
13 Department of Justice, or its successor agency;

14 (17)"Drug paraphernalia", all equipment, products, substances and materials of any kind
15 which are used, intended for use, or designed for use, in planting, propagating, cultivating, growing,
16 harvesting, manufacturing, compounding, converting, producing, processing, preparing, storing,
17 containing, concealing, injecting, ingesting, inhaling, or otherwise introducing into the human body
18 a controlled substance or an imitation controlled substance in violation of sections 195.005 to
19 195.425.It includes, but is not limited to:

20 (a)Kits used, intended for use, or designed for use in planting, propagating, cultivating,
21 growing or harvesting of any species of plant which is a controlled substance or from which a
22 controlled substance can be derived;

23 (b)Kits used, intended for use, or designed for use in manufacturing, compounding,
24 converting, producing, processing, or preparing controlled substances or imitation controlled
25 substances;

26 (c)Isomerization devices used, intended for use, or designed for use in increasing the potency
27 of any species of plant which is a controlled substance or an imitation controlled substance;

28 (d)Testing equipment used, intended for use, or designed for use in identifying, or in
29 analyzing the strength, effectiveness or purity of controlled substances or imitation controlled
30 substances;

31 (e)Scales and balances used, intended for use, or designed for use in weighing or measuring
32 controlled substances or imitation controlled substances;

33 (f)Dilutents and adulterants, such as quinine hydrochloride, mannitol, mannite, dextrose and
34 lactose, used, intended for use, or designed for use in cutting controlled substances or imitation
35 controlled substances;

36 (g)Separation gins and sifters used, intended for use, or designed for use in removing twigs
37 and seeds from, or in otherwise cleaning or refining, marijuana;

38 (h)Blenders, bowls, containers, spoons and mixing devices used, intended for use, or
39 designed for use in compounding controlled substances or imitation controlled substances;

40 (i)Capsules, balloons, envelopes and other containers used, intended for use, or designed for
41 use in packaging small quantities of controlled substances or imitation controlled substances;

42 (j)Containers and other objects used, intended for use, or designed for use in storing or
43 concealing controlled substances or imitation controlled substances;

44 (k)Hypodermic syringes, needles and other objects used, intended for use, or designed for use
45 in parenterally injecting controlled substances or imitation controlled substances into the human
46 body;

47 (l)Objects used, intended for use, or designed for use in ingesting, inhaling, or otherwise
48 introducing marijuana, cocaine, hashish, or hashish oil into the human body, such as:

1 a.Metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes with or without screens,
2 permanent screens, hashish heads, or punctured metal bowls;
3 b. Water pipes;
4 c. Carburetion tubes and devices;
5 d. Smoking and carburetion masks;
6 e. Roach clips meaning objects used to hold burning material, such as a marijuana cigarette,
7 that has become too small or too short to be held in the hand;
8 f. Miniature cocaine spoons and cocaine vials;
9 g. Chamber pipes;
10 h. Carburetor pipes;
11 i. Electric pipes;
12 j. Air-driven pipes;
13 k. Chillums;
14 l. Bongs;
15 m. Ice pipes or chillers;
16 (m) Substances used, intended for use, or designed for use in the manufacture of a controlled
17 substance; In determining whether an object, product, substance or material is drug paraphernalia, a
18 court or other authority should consider, in addition to all other logically relevant factors, the
19 following:
20 a. Statements by an owner or by anyone in control of the object concerning its use;
21 b. Prior convictions, if any, of an owner, or of anyone in control of the object, under any state
22 or federal law relating to any controlled substance or imitation controlled substance;
23 c. The proximity of the object, in time and space, to a direct violation of sections 195.005 to
24 195.425;
25 d. The proximity of the object to controlled substances or imitation controlled substances;
26 e. The existence of any residue of controlled substances or imitation controlled substances on
27 the object;
28 f. Direct or circumstantial evidence of the intent of an owner, or of anyone in control of the
29 object, to deliver it to persons who he knows, or should reasonably know, intend to use the object to
30 facilitate a violation of sections 195.005 to 195.425; the innocence of an owner, or of anyone in
31 control of the object, as to direct violation of sections 195.005 to 195.425 shall not prevent a finding
32 that the object is intended for use, or designed for use as drug paraphernalia;
33 g. Instructions, oral or written, provided with the object concerning its use;
34 h. Descriptive materials accompanying the object which explain or depict its use;
35 i. National or local advertising concerning its use;
36 j. The manner in which the object is displayed for sale;
37 k. Whether the owner, or anyone in control of the object, is a legitimate supplier of like or
38 related items to the community, such as a licensed distributor or dealer of tobacco products;
39 l. Direct or circumstantial evidence of the ratio of sales of the object to the total sales of the
40 business enterprise;
41 m. The existence and scope of legitimate uses for the object in the community;
42 n. Expert testimony concerning its use;
43 o. The quantity, form or packaging of the product, substance or material in relation to the
44 quantity, form or packaging associated with any legitimate use for the product, substance or material;
45 (18) "Federal narcotic laws", the laws of the United States relating to controlled substances;
46 (19) "Hospital", a place devoted primarily to the maintenance and operation of facilities for
47 the diagnosis, treatment or care, for not less than twenty-four hours in any week, of three or more
48 nonrelated individuals suffering from illness, disease, injury, deformity or other abnormal physical

1 conditions; or a place devoted primarily to provide, for not less than twenty-four consecutive hours
2 in any week, medical or nursing care for three or more nonrelated individuals. The term "hospital"
3 does not include convalescent, nursing, shelter or boarding homes as defined in chapter 198;

4 (20)"Immediate precursor", a substance which:

5 (a)The state department of health and senior services has found to be and by rule designates
6 as being the principal compound commonly used or produced primarily for use in the manufacture of
7 a controlled substance;

8 (b)Is an immediate chemical intermediary used or likely to be used in the manufacture of a
9 controlled substance; and

10 (c)The control of which is necessary to prevent, curtail or limit the manufacture of the
11 controlled substance;

12 (21)"Imitation controlled substance", a substance that is not a controlled substance, which by
13 dosage unit appearance (including color, shape, size and markings), or by representations made,
14 would lead a reasonable person to believe that the substance is a controlled substance. In determining
15 whether the substance is an imitation controlled substance the court or authority concerned should
16 consider, in addition to all other logically relevant factors, the following:

17 (a)Whether the substance was approved by the federal Food and Drug Administration for
18 over-the-counter (nonprescription or nonlegend) sales and was sold in the federal Food and Drug
19 Administration approved package, with the federal Food and Drug Administration approved labeling
20 information;

21 (b)Statements made by an owner or by anyone else in control of the substance concerning the
22 nature of the substance, or its use or effect;

23 (c)Whether the substance is packaged in a manner normally used for illicit controlled
24 substances;

25 (d)Prior convictions, if any, of an owner, or anyone in control of the object, under state or
26 federal law related to controlled substances or fraud;

27 (e)The proximity of the substances to controlled substances;

28 (f)Whether the consideration tendered in exchange for the noncontrolled substance
29 substantially exceeds the reasonable value of the substance considering the actual chemical
30 composition of the substance and, where applicable, the price at which over-the-counter substances
31 of like chemical composition sell. An imitation controlled substance does not include a placebo or
32 registered investigational drug either of which was manufactured, distributed, possessed or delivered
33 in the ordinary course of professional practice or research;

34 (22)"Laboratory", a laboratory approved by the department of health and senior services as
35 proper to be entrusted with the custody of controlled substances but does not include a pharmacist
36 who compounds controlled substances to be sold or dispensed on prescriptions;

37 (23)"Manufacture", the production, preparation, propagation, compounding or processing of
38 drug paraphernalia or of a controlled substance, or an imitation controlled substance, either directly
39 or by extraction from substances of natural origin, or independently by means of chemical synthesis,
40 or by a combination of extraction and chemical synthesis, and includes any packaging or
41 repackaging of the substance or labeling or relabeling of its container. This term does not include the
42 preparation or compounding of a controlled substance or an imitation controlled substance or the
43 preparation, compounding, packaging or labeling of a narcotic or dangerous drug:

44 (a)By a practitioner as an incident to his administering or dispensing of a controlled
45 substance or an imitation controlled substance in the course of his professional practice, or

46 (b)By a practitioner or his authorized agent under his supervision, for the purpose of, or as an
47 incident to, research, teaching or chemical analysis and not for sale;

48 (24)"Marijuana", all parts of the plant genus Cannabis in any species or form thereof,

1 including, but not limited to Cannabis Sativa L., Cannabis Indica, Cannabis Americana, Cannabis
2 Ruderalis, and Cannabis Gigantea, whether growing or not, the seeds thereof, the resin extracted
3 from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or
4 preparation of the plant, its seeds or resin. It does not include the mature stalks of the plant, fiber
5 produced from the stalks, oil or cake made from the seeds of the plant, any other compound,
6 manufacture, salt, derivative, mixture or preparation of the mature stalks (except the resin extracted
7 therefrom), fiber, oil or cake, or the sterilized seed of the plant which is incapable of germination;

8 (25) "Methamphetamine precursor drug", any drug containing ephedrine, pseudoephedrine,
9 phenylpropanolamine, or any of their salts, optical isomers, or salts of optical isomers;

10 (26) "Narcotic drug", any of the following, whether produced directly or indirectly by
11 extraction from substances of vegetable origin, or independently by means of chemical synthesis, or
12 by a combination of extraction and chemical analysis:

13 (a) Opium, opiate, and any derivative, of opium or opiate, including their isomers, esters,
14 ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters,
15 ethers, and salts is possible within the specific chemical designation. The term does not include the
16 isoquinoline alkaloids of opium;

17 (b) Coca leaves, but not including extracts of coca leaves from which cocaine, ecgonine, and
18 derivatives of ecgonine or their salts have been removed;

19 (c) Cocaine or any salt, isomer, or salt of isomer thereof;

20 (d) Ecgonine, or any derivative, salt, isomer, or salt of isomer thereof;

21 (e) Any compound, mixture, or preparation containing any quantity of any substance referred
22 to in paragraphs (a) to (d) of this subdivision;

23 (27) "Official written order", an order written on a form provided for that purpose by the
24 United States Commissioner of Narcotics, under any laws of the United States making provision
25 therefor, if such order forms are authorized and required by federal law, and if no such order form is
26 provided, then on an official form provided for that purpose by the department of health and senior
27 services;

28 (28) "Opiate", any substance having an addiction-forming or addiction-sustaining liability
29 similar to morphine or being capable of conversion into a drug having addiction-forming or
30 addiction-sustaining liability. The term includes its racemic and levorotatory forms. It does not
31 include, unless specifically controlled under section 195.017, the dextrorotatory isomer of
32 3-methoxy-n-methyl-morphinan and its salts (dextromethorphan);

33 (29) "Opium poppy", the plant of the species *Papaver somniferum* L., except its seeds;

34 (30) "Over-the-counter sale", a retail sale licensed pursuant to chapter 144 of a drug other than
35 a controlled substance;

36 (31) "Person", an individual, corporation, government or governmental subdivision or agency,
37 business trust, estate, trust, partnership, joint venture, association, or any other legal or commercial
38 entity;

39 (32) "Pharmacist", a licensed pharmacist as defined by the laws of this state, and where the
40 context so requires, the owner of a store or other place of business where controlled substances are
41 compounded or dispensed by a licensed pharmacist; but nothing in sections 195.005 to 195.425 shall
42 be construed as conferring on a person who is not registered nor licensed as a pharmacist any
43 authority, right or privilege that is not granted to him by the pharmacy laws of this state;

44 (33) "Poppy straw", all parts, except the seeds, of the opium poppy, after mowing;

45 (34) "Possessed" or "possessing a controlled substance", a person, with the knowledge of the
46 presence and nature of a substance, has actual or constructive possession of the substance. A person
47 has actual possession if he has the substance on his person or within easy reach and convenient
48 control. A person who, although not in actual possession, has the power and the intention at a given

time to exercise dominion or control over the substance either directly or through another person or persons is in constructive possession of it. Possession may also be sole or joint. If one person alone has possession of a substance possession is sole. If two or more persons share possession of a substance, possession is joint;

(35) "Practitioner", a physician, dentist, optometrist, podiatrist, veterinarian, scientific investigator, pharmacy, hospital or other person licensed, registered or otherwise permitted by this state to distribute, dispense, conduct research with respect to or administer or to use in teaching or chemical analysis, a controlled substance in the course of professional practice or research in this state, or a pharmacy, hospital or other institution licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to or administer a controlled substance in the course of professional practice or research;

(36) "Production", includes the manufacture, planting, cultivation, growing, or harvesting of drug paraphernalia or of a controlled substance or an imitation controlled substance;

(37) "Registry number", the number assigned to each person registered under the federal controlled substances laws;

(38) "Sale", includes barter, exchange, or gift, or offer therefor, and each such transaction made by any person, whether as principal, proprietor, agent, servant or employee;

(39) "State" when applied to a part of the United States, includes any state, district, commonwealth, territory, insular possession thereof, and any area subject to the legal authority of the United States of America;

(40) "Synthetic cannabinoid"[.] includes unless specifically excepted or unless listed in another schedule, any natural or synthetic material, compound, mixture, or preparation that contains any quantity of a substance that is a cannabinoid receptor agonist, including but not limited to any substance listed in paragraph (11) of subdivision (4) of subsection 2 of section 195.017 and any analogues, homologues; isomers, whether optical, positional, or geometric; esters; ethers; salts; and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters, ethers, or salts is possible within the specific chemical designation, however, it shall not include any approved pharmaceutical authorized by the United States Food and Drug Administration;

(41) "Ultimate user", a person who lawfully possesses a controlled substance or an imitation controlled substance for his own use or for the use of a member of his household or for administering to an animal owned by him or by a member of his household;

(42) "Wholesaler", a person who supplies drug paraphernalia or controlled substances or imitation controlled substances that he himself has not produced or prepared, on official written orders, but not on prescriptions.

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

(1) Has high potential for abuse; and

(2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

(1) The controlled substances listed in this subsection are included in Schedule I;

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl-alpha-methylfentanyl;

(b) Acetylmethadol;

(c) Allylprodine;

(d) Alphacetylmethadol;

- 1 (e) Alphameprodine;
- 2 (f) Alphamethadol;
- 3 (g) Alpha-methylfentanyl;
- 4 (h) Alpha-methylthiofentanyl;
- 5 (i) Benzethidine;
- 6 (j) Betacetylmethadol;
- 7 (k) Beta-hydroxyfentanyl;
- 8 (l) Beta-hydroxy-3-methylfentanyl;
- 9 (m) Betameprodine;
- 10 (n) Betamethadol;
- 11 (o) Betaprodine;
- 12 (p) Clonitazene;
- 13 (q) Dextromoramide;
- 14 (r) Diampromide;
- 15 (s) Diethylthiambutene;
- 16 (t) Difenoxin;
- 17 (u) Dimenoxadol;
- 18 (v) Dimepheptanol;
- 19 (w) Dimethylthiambutene;
- 20 (x) Dioxaphetyl butyrate;
- 21 (y) Dipipanone;
- 22 (z) Ethylmethylthiambutene;
- 23 (aa) Etonitazene;
- 24 (bb) Etoxidine;
- 25 (cc) Furethidine;
- 26 (dd) Hydroxypethidine;
- 27 (ee) Ketobemidone;
- 28 (ff) Levomoramide;
- 29 (gg) Levophenacymorphan;
- 30 (hh) 3-Methylfentanyl;
- 31 (ii) 3-Methylthiofentanyl;
- 32 (jj) Morpheridine;
- 33 (kk) MPPP;
- 34 (ll) Noracymethadol;
- 35 (mm) Norlevorphanol;
- 36 (nn) Normethadone;
- 37 (oo) Norpipanone;
- 38 (pp) Para-fluorofentanyl;
- 39 (qq) PEPAP;
- 40 (rr) Phenadoxone;
- 41 (ss) Phenampromide;
- 42 (tt) Phenomorphan;
- 43 (uu) Phenoperidine;
- 44 (vv) Piritramide;
- 45 (ww) Proheptazine;
- 46 (xx) Properidine;
- 47 (yy) Propiram;
- 48 (zz) Racemoramide;

1 (aaa) Thiofentanyl;
 2 (bbb) Tilidine;
 3 (ccc) Trimeperidine;
 4 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers unless
 5 specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible
 6 within the specific chemical designation:

- 7 (a) Acetorphine;
- 8 (b) Acetyldihydrocodeine;
- 9 (c) Benzylmorphine;
- 10 (d) Codeine methylbromide;
- 11 (e) Codeine-N-Oxide;
- 12 (f) Cyprenorphine;
- 13 (g) Desomorphine;
- 14 (h) Dihydromorphine;
- 15 (i) Drotebanol;
- 16 (j) Etorphine (except hydrochloride salt);
- 17 (k) Heroin;
- 18 (l) Hydromorphenol;
- 19 (m) Methyldesorphine;
- 20 (n) Methyldihydromorphine;
- 21 (o) Morphine methylbromide;
- 22 (p) Morphine methylsulfonate;
- 23 (q) Morphine-N-Oxide;
- 24 (r) Myrophine;
- 25 (s) Nicocodeine;
- 26 (t) Nicomorphine;
- 27 (u) Normorphine;
- 28 (v) Pholcodine;
- 29 (w) Thebacon;

30 (4) Any material, compound, mixture or preparation which contains any quantity of the
 31 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
 32 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the
 33 specific chemical designation:

- 34 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 35 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 36 (c) 2,5-dimethoxyamphetamine;
- 37 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 38 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 39 (f) 4-methoxyamphetamine;
- 40 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 41 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 42 (i) 3,4-methylenedioxyamphetamine;
- 43 (j) 3,4-methylenedioxymethamphetamine;
- 44 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 45 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 46 (m) 3,4,5-trimethoxyamphetamine;
- 47 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts, and salts of
 48 isomers;

- (o) Alpha-ethyltryptamine;
- (p) Alpha-methyltryptamine;
- (q) Bufotenine;
- (r) Diethyltryptamine;
- (s) Dimethyltryptamine;
- (t) 5-methoxy-N,N-diisopropyltryptamine;
- (u) Ibogaine;
- (v) Lysergic acid diethylamide;
- (w) Marijuana or marihuana;
- (x) Mescaline;
- (y) Parahexyl;
- (z) Peyote, to include all parts of the plant presently classified botanically as *Lophophora Williamsii* Lemaire, whether growing or not; the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seed or extracts;
- (aa) N-ethyl-3-piperidyl benzilate;
- (bb) N-methyl-3-piperidyl benzilate;
- (cc) Psilocybin;
- (dd) Psilocyn;
- (ee) Tetrahydrocannabinols naturally contained in a plant of the genus *Cannabis* (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of such plant, or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following:
 - a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
 - b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
 - c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
 - d. Any compounds of these structures, regardless of numerical designation of atomic positions covered;
 - (ff) Ethylamine analog of phencyclidine;
 - (gg) Pyrrolidine analog of phencyclidine;
 - (hh) Thiophene analog of phencyclidine;
 - (ii) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
 - (jj) *Salvia divinorum*;
 - (kk) Salvinorin A;
 - (ll) Synthetic cannabinoids:
 - a. Any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Including, but not limited to:
 - (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;
 - (ii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;
 - (iii) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;
 - (iv) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;
 - (v) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;
 - (vi) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
 - (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;

- (viii) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;
- (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
- (x) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
- (xi) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
- (xii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
- b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent;
- c. Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent;
- d. Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Including, but not limited to:
- (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;
- (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;
- (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;
- (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;
- (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;
- e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent. Including, but not limited to:
- (i) CP 47, 497 & homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol, where side chain n=5, and homologues where side chain n=4,6, or 7;
- f. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Including, but not limited to:
- (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
- (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole;
- g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;
- h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
- i. HU-211, or Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
- j. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;
- k. Dimethylheptylpyran, or DMHP;
- (5) Any material, compound, mixture or preparation containing any quantity of the

following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

- (a) Gamma-hydroxybutyric acid;
- (b) Mecloqualone;
- (c) Methaqualone;

(6) Any material, compound, mixture or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers and salts of isomers:

- (a) Aminorex;
- (b) N-benzylpiperazine;
- (c) Cathinone;
- (d) Fenethylline;
- (e) 3-Fluoromethcathinone;
- (f) 4-Fluoromethcathinone;
- (g) Mephedrone, or 4-methylmethcathinone;
- (h) Methcathinone;
- (i) 4-methoxymethcathinone;
- (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazoline);
- (k) Methylenedioxypyrovalerone, MDPV, or (1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone);
- (l) Methylone, or 3,4-Methylenedioxymethcathinone;
- (m) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP;
- (n) N-ethylamphetamine;
- (o) N,N-dimethylamphetamine;

(7) A temporary listing of substances subject to emergency scheduling under federal law shall include any material, compound, mixture or preparation which contains any quantity of the following substances:

- (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of isomers;
- (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its optical isomers, salts and salts of isomers;

(8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*, whether growing or not; the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.

3. The department of health and senior services shall place a substance in Schedule II if it finds that:

- (1) The substance has high potential for abuse;
- (2) The substance has currently accepted medical use in treatment in the United States, or currently accepted medical use with severe restrictions; and

(3) The abuse of the substance may lead to severe psychic or physical dependence.

4. The controlled substances listed in this subsection are included in Schedule II:

(1) Any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

(a) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone, and their respective salts but including the following:

- 1 a. Raw opium;
- 2 b. Opium extracts;
- 3 c. Opium fluid;
- 4 d. Powdered opium;
- 5 e. Granulated opium;
- 6 f. Tincture of opium;
- 7 g. Codeine;
- 8 h. Ethylmorphine;
- 9 i. Etorphine hydrochloride;
- 10 j. Hydrocodone;
- 11 k. Hydromorphone;
- 12 l. Metopon;
- 13 m. Morphine;
- 14 n. Oxycodone;
- 15 o. Oxymorphone;
- 16 p. Thebaine;
- 17 (b) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or
- 18 identical with any of the substances referred to in this subdivision, but not including the isoquinoline
- 19 alkaloids of opium;
- 20 (c) Opium poppy and poppy straw;
- 21 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any
- 22 salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with
- 23 any of these substances, but not including decocainized coca leaves or extractions which do not
- 24 contain cocaine or ecgonine;
- 25 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or
- 26 powder form which contains the phenanthrene alkaloids of the opium poppy);
- 27 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of
- 28 isomers, whenever the existence of these isomers, esters, ethers and salts is possible within the
- 29 specific chemical designation, dextrorphan and levopropoxyphene excepted:
- 30 (a) Alfentanil;
- 31 (b) Alphaprodine;
- 32 (c) Anileridine;
- 33 (d) Bezitramide;
- 34 (e) Bulk dextropropoxyphene;
- 35 (f) Carfentanil;
- 36 (g) Dihydrocodeine;
- 37 (h) Diphenoxylate;
- 38 (i) Fentanyl;
- 39 (j) Isomethadone;
- 40 (k) Levo-alphacetylmethadol;
- 41 (l) Levomethorphan;
- 42 (m) Levorphanol;
- 43 (n) Metazocine;
- 44 (o) Methadone;
- 45 (p) Meperidine;
- 46 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
- 47 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic acid;
- 48 (s) Pethidine (meperidine);

- (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
 - (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
 - (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
 - (w) Phenazocine;
 - (x) Piminodine;
 - (y) Racemethorphan;
 - (z) Racemorphan;
 - (aa) Remifentanil;
 - (bb) Sufentanil;
 - (cc) Tapentadol;
 - (3) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:
 - (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
 - (b) Lisdexamphetamine, its salts, isomers, and salts of its isomers;
 - (c) Methamphetamine, its salts, isomers, and salts of its isomers;
 - (d) Phenmetrazine and its salts;
 - (e) Methylphenidate;
 - (4) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation:
 - (a) Amobarbital;
 - (b) Glutethimide;
 - (c) Pentobarbital;
 - (d) Phencyclidine;
 - (e) Secobarbital;
 - (5) Any material or compound which contains any quantity of nabilone;
 - (6) Any material, compound, mixture, or preparation which contains any quantity of the following substances:
 - (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
 - (b) Immediate precursors to phencyclidine (PCP):
 - a. 1-phenylcyclohexylamine;
 - b. 1-piperidinocyclohexanecarbonitrile (PCC);
 - (7) Any material, compound, mixture, or preparation which contains any quantity of the following alkyl nitrites:
 - (a) Amyl nitrite;
 - (b) Butyl nitrite.
5. The department of health and senior services shall place a substance in Schedule III if it finds that:
- (1) The substance has a potential for abuse less than the substances listed in Schedules I and II;
 - (2) The substance has currently accepted medical use in treatment in the United States; and
 - (3) Abuse of the substance may lead to moderate or low physical dependence or high psychological dependence.
6. The controlled substances listed in this subsection are included in Schedule III:
- (1) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:

- 1 (a) Benzphetamine;
2 (b) Chlorphentermine;
3 (c) Clortermine;
4 (d) Phendimetrazine;
5 (2) Any material, compound, mixture or preparation which contains any quantity or salt of
6 the following substances or salts having a depressant effect on the central nervous system:
7 (a) Any material, compound, mixture or preparation which contains any quantity or salt of
8 the following substances combined with one or more active medicinal ingredients:
9 a. Amobarbital;
10 b. Secobarbital;
11 c. Pentobarbital;
12 (b) Any suppository dosage form containing any quantity or salt of the following:
13 a. Amobarbital;
14 b. Secobarbital;
15 c. Pentobarbital;
16 (c) Any substance which contains any quantity of a derivative of barbituric acid or its salt;
17 (d) Chlorhexadol;
18 (e) Embutramide;
19 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in a
20 drug product for which an application has been approved under Section 505 of the federal Food,
21 Drug, and Cosmetic Act;
22 (g) Ketamine, its salts, isomers, and salts of isomers;
23 (h) Lysergic acid;
24 (i) Lysergic acid amide;
25 (j) Methypylon;
26 (k) Sulfondiethylmethane;
27 (l) Sulfonethylmethane;
28 (m) Sulfonmethane;
29 (n) Tiletamine and zolazepam or any salt thereof;
30 (3) Nalorphine;
31 (4) Any material, compound, mixture, or preparation containing limited quantities of any of
32 the following narcotic drugs or their salts:
33 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than ninety
34 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
35 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than ninety
36 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
37 therapeutic amounts;
38 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters or
39 not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
40 isoquinoline alkaloid of opium;
41 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters or
42 not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic ingredients in
43 recognized therapeutic amounts;
44 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more than
45 ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized
46 therapeutic amounts;
47 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters or
48 not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic ingredients in

1 recognized therapeutic amounts;

2 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per one
3 hundred grams or not more than twenty-five milligrams per dosage unit, with one or more active
4 nonnarcotic ingredients in recognized therapeutic amounts;

5 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
6 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

7 (5) Any material, compound, mixture, or preparation containing any of the following
8 narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

9 (6) Anabolic steroids. Any drug or hormonal substance, chemically and pharmacologically
10 related to testosterone (other than estrogens, progestins, corticosteroids, and
11 dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is expressly
12 intended for administration through implants to cattle or other nonhuman species and which has been
13 approved by the Secretary of Health and Human Services for that administration. If any person
14 prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to
15 have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subdivision.
16 Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or
17 preparation containing any quantity of the following substances, including its salts, esters and ethers:

- 18 (a) 3 β ,17-dihydroxy-5 α -androstane;
- 19 (b) 3 α ,17 β -dihydroxy-5 α -androstane;
- 20 (c) 5 α -androstane-3,17-dione;
- 21 (d) 1-androstenediol (3 β ,17 β -dihydroxy-5 α -androst-1-ene);
- 22 (e) 1-androstenediol (3 α ,17 β -dihydroxy-5 α -androst-1-ene);
- 23 (f) 4-androstenediol (3 β ,17 β -dihydroxy-androst-4-ene);
- 24 (g) 5-androstenediol (3 β ,17 β -dihydroxy-androst-5-ene);
- 25 (h) 1-androstenedione ([5 α]-androst-1-en-3,17-dione);
- 26 (i) 4-androstenedione (androst-4-en-3,17-dione);
- 27 (j) 5-androstenedione (androst-5-en-3,17-dione);
- 28 (k) Bolasterone (7 α , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
- 29 (l) Boldenone (17 β -hydroxyandrost-1,4,-diene-3-one);
- 30 (m) Boldione;
- 31 (n) Calusterone (7 β , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
- 32 (o) Clostebol (4-chloro-17 β -hydroxyandrost-4-en-3-one);
- 33 (p) Dehydrochloromethyltestosterone (4-chloro-17 β -hydroxy-17 α -methyl-androst-1,
34 4-dien-3-one);
- 35 (q) Desoxymethyltestosterone;
- 36 (r) ?1-dihydrotestosterone (a.k.a. '1-testosterone')(17 β -hydroxy-5 α -androst-1-en-3-one);
- 37 (s) 4-dihydrotestosterone (17 β -hydroxy-androstan-3-one);
- 38 (t) Drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstan-3-one);
- 39 (u) Ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
- 40 (v) Fluoxymesterone (9-fluoro-17 α -methyl-11 β ,17 β -dihydroxyandrost-4-en-3-one);
- 41 (w) Formebolone (2-formyl-17 α -methyl-11 α ,17 β -dihydroxyandrost-1,4-dien-3-one);
- 42 (x) Furazabol (17 α -methyl-17 β -hydroxyandrostano[2,3-c]-furazan);
- 43 (y) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
- 44 (z) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
- 45 (aa) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);
- 46 (bb) Mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-one);
- 47 (cc) Mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one);
- 48 (dd) Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);

- 1 (ee) Methandriol (17a-methyl-3 β ,17 β -dihydroxyandrost-5-ene);
 2 (ff) Methenolone (1-methyl-17 β -hydroxy-5a-androst-1-en-3-one);
 3 (gg) 17a-methyl-3 β ,17 β -dihydroxy-5a-androstane);
 4 (hh) 17a-methyl-3a,17 β -dihydroxy-5a-androstane);
 5 (ii) 17a-methyl-3 β ,17 β -dihydroxyandrost-4-ene;
 6 (jj) 17a-methyl-4-hydroxynandrolone (17a-methyl-4-hydroxy-17 β -hydroxyestr-4-en-
 7 3-one);
 8 (kk) Methyldienolone (17a-methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
 9 (ll) Methyltrienolone (17a-methyl-17 β -hydroxyestra-4,9,11-trien-3-one);
 10 (mm) Methyltestosterone (17a-methyl-17 β -hydroxyandrost-4-en-3-one);
 11 (nn) Mibolerone (7a,17a-dimethyl-17 β -hydroxyestr-4-en-3-one);
 12 (oo) 17a-methyl- Δ 1-dihydrotestosterone (17 β -hydroxy-17a-methyl-5a-androst-1-en-
 13 3-one) (a.k.a. '17-a-methyl-1-testosterone');
 14 (pp) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
 15 (qq) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
 16 (rr) 19-nor-4-androstenediol (3a,17 β -dihydroxyestr-4-ene);
 17 (ss) 19-nor-4,9(10)-androstadienedione;
 18 (tt) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
 19 (uu) 19-nor-5-androstenediol (3a,17 β -dihydroxyestr-5-ene);
 20 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
 21 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
 22 (xx) Norbolethone (13 β ,17a-diethyl-17 β -hydroxygon-4-en-3-one);
 23 (yy) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
 24 (zz) Norethandrolone (17a-ethyl-17 β -hydroxyestr-4-en-3-one);
 25 (aaa) Normethandrolone (17a-methyl-17 β -hydroxyestr-4-en-3-one);
 26 (bbb) Oxandrolone (17a-methyl-17 β -hydroxy-2-oxa-[5a]-androstan-3-one);
 27 (ccc) Oxymesterone (17a-methyl-4,17 β -dihydroxyandrost-4-en-3-one);
 28 (ddd) Oxymethalone (17a-methyl-2-hydroxymethylene-17 β -hydroxy-[5a]-androstan-
 29 3-one);
 30 (eee) Stanozolol (17a-methyl-17 β -hydroxy-[5a]-androst-2-eno[3,2-c]-pyrazole);
 31 (fff) Stenbolone (17 β -hydroxy-2-methyl-[5a]-androst-1-en-3-one);
 32 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
 33 (hhh) Testosterone (17 β -hydroxyandrost-4-en-3-one);
 34 (iii) Tetrahydrogestrinone (13 β ,17a-diethyl-17 β -hydroxygon-4,9,11-trien-3-one);
 35 (jjj) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
 36 (kkk) Any salt, ester, or ether of a drug or substance described or listed in this subdivision,
 37 except an anabolic steroid which is expressly intended for administration through implants to cattle
 38 or other nonhuman species and which has been approved by the Secretary of Health and Human
 39 Services for that administration;
 40 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
 41 United States Food and Drug Administration approved drug product;
 42 (8) The department of health and senior services may except by rule any compound, mixture,
 43 or preparation containing any stimulant or depressant substance listed in subdivisions (1) and (2) of
 44 this subsection from the application of all or any part of sections 195.010 to 195.320 if the
 45 compound, mixture, or preparation contains one or more active medicinal ingredients not having a
 46 stimulant or depressant effect on the central nervous system, and if the admixtures are included
 47 therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of
 48 the substances which have a stimulant or depressant effect on the central nervous system.

1 7. The department of health and senior services shall place a substance in Schedule IV if it
2 finds that:

- 3 (1) The substance has a low potential for abuse relative to substances in Schedule III;
4 (2) The substance has currently accepted medical use in treatment in the United States; and
5 (3) Abuse of the substance may lead to limited physical dependence or psychological
6 dependence relative to the substances in Schedule III.

7 8. The controlled substances listed in this subsection are included in Schedule IV:

8 (1) Any material, compound, mixture, or preparation containing any of the following
9 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as
10 set forth below:

11 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms of
12 atropine sulfate per dosage unit;

13 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
14 propionoxybutane);

15 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
16 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon
17 the compound, mixture or preparation valuable medicinal qualities other than those possessed by the
18 narcotic drug alone:

19 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per one
20 hundred grams;

21 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters or
22 per one hundred grams;

23 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters or per
24 one hundred grams;

25 (2) Any material, compound, mixture or preparation containing any quantity of the
26 following substances, including their salts, isomers, and salts of isomers whenever the existence of
27 those salts, isomers, and salts of isomers is possible within the specific chemical designation:

28 (a) Alprazolam;

29 (b) Barbital;

30 (c) Bromazepam;

31 (d) Camazepam;

32 (e) Chloral betaine;

33 (f) Chloral hydrate;

34 (g) Chlordiazepoxide;

35 (h) Clobazam;

36 (i) Clonazepam;

37 (j) Clorazepate;

38 (k) Clotiazepam;

39 (l) Cloxazolam;

40 (m) Delorazepam;

41 (n) Diazepam;

42 (o) Dichloralphenazone;

43 (p) Estazolam;

44 (q) Ethchlorvynol;

45 (r) Ethinamate;

46 (s) Ethyl loflazepate;

47 (t) Fludiazepam;

48 (u) Flunitrazepam;

- (v) Flurazepam;
- (w) Fospropofol;
- (x) Halazepam;
- (y) Haloxazolam;
- (z) Ketazolam;
- (aa) Loprazolam;
- (bb) Lorazepam;
- (cc) Lormetazepam;
- (dd) Mebutamate;
- (ee) Medazepam;
- (ff) Meprobamate;
- (gg) Methohexital;
- (hh) Methylphenobarbital (mephobarbital);
- (ii) Midazolam;
- (jj) Nimetazepam;
- (kk) Nitrazepam;
- (ll) Nordiazepam;
- (mm) Oxazepam;
- (nn) Oxazolam;
- (oo) Paraldehyde;
- (pp) Petrichloral;
- (qq) Phenobarbital;
- (rr) Pinazepam;
- (ss) Prazepam;
- (tt) Quazepam;
- (uu) Temazepam;
- (vv) Tetrazepam;
- (ww) Triazolam;
- (xx) Zaleplon;
- (yy) Zolpidem;
- (zz) Zopiclone;

(3) Any material, compound, mixture, or preparation which contains any quantity of the following substance including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible: fenfluramine;

(4) Any material, compound, mixture or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers and salts of isomers:

- (a) Cathine ((+)-norpseudoephedrine);
- (b) Diethylpropion;
- (c) Fencamfamin;
- (d) Fenproporex;
- (e) Mazindol;
- (f) Mefenorex;
- (g) Modafinil;
- (h) Pemoline, including organometallic complexes and chelates thereof;
- (i) Phentermine;
- (j) Pipradrol;
- (k) Sibutramine;

- 1 (1) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
2 (5) Any material, compound, mixture or preparation containing any quantity of the
3 following substance, including its salts:
4 (a) butorphanol;
5 (b) pentazocine;
6 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance is
7 the only active medicinal ingredient;
8 (7) The department of health and senior services may except by rule any compound, mixture,
9 or preparation containing any depressant substance listed in subdivision (1) of this subsection from
10 the application of all or any part of sections 195.010 to 195.320 and sections 579.015 to 579.086 if
11 the compound, mixture, or preparation contains one or more active medicinal ingredients not having
12 a depressant effect on the central nervous system, and if the admixtures are included therein in
13 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
14 substances which have a depressant effect on the central nervous system.
15 9. The department of health and senior services shall place a substance in Schedule V if it
16 finds that:
17 (1) The substance has low potential for abuse relative to the controlled substances listed in
18 Schedule IV;
19 (2) The substance has currently accepted medical use in treatment in the United States; and
20 (3) The substance has limited physical dependence or psychological dependence liability
21 relative to the controlled substances listed in Schedule IV.
22 10. The controlled substances listed in this subsection are included in Schedule V:
23 (1) Any compound, mixture or preparation containing any of the following narcotic drugs or
24 their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below,
25 which also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to
26 confer upon the compound, mixture or preparation valuable medicinal qualities other than those
27 possessed by the narcotic drug alone:
28 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
29 twenty-five micrograms of atropine sulfate per dosage unit;
30 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per one
31 hundred grams;
32 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
33 micrograms of atropine sulfate per dosage unit;
34 (2) Any material, compound, mixture or preparation which contains any quantity of the
35 following substance having a stimulant effect on the central nervous system including its salts,
36 isomers and salts of isomers: pyrovalerone;
37 (3) Any compound, mixture, or preparation containing any detectable quantity of
38 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound, mixture,
39 or preparation containing any detectable quantity of ephedrine or its salts or optical isomers, or salts
40 of optical isomers;
41 (4) Unless specifically exempted or excluded or unless listed in another schedule, any
42 material, compound, mixture, or preparation which contains any quantity of the following substances
43 having a depressant effect on the central nervous system, including its salts:
44 (a) Lacosamide;
45 (b) Pregabalin.
46 11. If any compound, mixture, or preparation as specified in subdivision (3) of subsection 10
47 of this section is dispensed, sold, or distributed in a pharmacy without a prescription:
48 (1) All packages of any compound, mixture, or preparation containing any detectable

1 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine, its
2 salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind a
3 pharmacy counter where the public is not permitted, and only by a registered pharmacist or
4 registered pharmacy technician; and

5 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture, or
6 preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers, or
7 salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers shall be at
8 least eighteen years of age; and

9 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require any
10 person, prior to such person's purchasing, receiving or otherwise acquiring such compound, mixture,
11 or preparation to furnish suitable photo identification that is issued by a state or the federal
12 government or a document that, with respect to identification, is considered acceptable and showing
13 the date of birth of the person;

14 (4) The seller shall deliver the product directly into the custody of the purchaser.

15 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall implement
16 and maintain an electronic log of each transaction. Such log shall include the following information:

17 (1) The name, address, and signature of the purchaser;

18 (2) The amount of the compound, mixture, or preparation purchased;

19 (3) The date and time of each purchase; and

20 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
21 technician who dispensed the compound, mixture, or preparation to the purchaser.

22 13. Each pharmacy shall submit information regarding sales of any compound, mixture, or
23 preparation as specified in subdivision (3) of subsection 10 of this section in accordance with
24 transmission methods and frequency established by the department by regulation;

25 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities greater
26 than those specified in this chapter.

27 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products in a
28 pharmacy shall ensure that all such products are located only behind a pharmacy counter where the
29 public is not permitted.

30 16. The penalties for a knowing or reckless violation of the provisions of subsections 11 to
31 15 of this section are found in section 579.060.

32 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this section
33 and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds, mixtures, or
34 preparations that are in liquid or liquid-filled gel capsule form or to any compound, mixture, or
35 preparation specified in subdivision (3) of subsection 10 of this section which must be dispensed,
36 sold, or distributed in a pharmacy pursuant to a prescription.

37 18. The manufacturer of a drug product or another interested party may apply with the
38 department of health and senior services for an exemption from this section. The department of
39 health and senior services may grant an exemption by rule from this section if the department finds
40 the drug product is not used in the illegal manufacture of methamphetamine or other controlled or
41 dangerous substances. The department of health and senior services shall rely on reports from law
42 enforcement and law enforcement evidentiary laboratories in determining if the proposed product
43 can be used to manufacture illicit controlled substances.

44 19. The department of health and senior services shall revise and republish the schedules
45 annually.

46 20. The department of health and senior services shall promulgate rules under chapter 536
47 regarding the security and storage of Schedule V controlled substances, as described in subdivision
48 (3) of subsection 10 of this section, for distributors as registered by the department of health and

1 senior services.

2 21. Logs of transactions required to be kept and maintained by this section and section
3 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is the
4 person whose transactions are recorded in the logs.

5 22. Beginning January 1, 2017, the director of the department of health and senior services
6 shall notify the revisor of statutes of any controlled substances that are added or removed from the
7 five schedules of controlled substances established by the federal Controlled Substances Act under
8 21 U.S.C. section 801, et seq. The revisor shall change the statutory schedule of controlled
9 substances listed in this section to include such additions or deletions.

10 217.720.1. At any time during release on parole or conditional release the board [may] shall
11 issue a warrant for the arrest of a released offender for violation of any of the conditions of parole or
12 conditional release. The warrant shall authorize any law enforcement officer to return the offender to
13 the actual custody of the correctional center from which the offender was released, or to any other
14 suitable facility designated by the board. If any parole or probation officer has probable cause to
15 believe that such offender has violated a condition of parole or conditional release, the probation or
16 parole officer [may] shall issue a warrant for the arrest of the offender. The probation or parole
17 officer may effect the arrest or may deputize any officer with the power of arrest to do so by giving
18 the officer a copy of the warrant which shall outline the circumstances of the alleged violation and
19 contain the statement that the offender has, in the judgment of the probation or parole officer,
20 violated conditions of parole or conditional release. The warrant delivered with the offender by the
21 arresting officer to the official in charge of any facility designated by the board to which the offender
22 is brought shall be sufficient legal authority for detaining the offender. After the arrest the parole or
23 probation officer shall present to the detaining authorities a similar statement of the circumstances of
24 violation. Pending hearing as hereinafter provided, upon any charge of violation, the offender shall
25 remain in custody or incarcerated without consideration of bail.

26 2. If the offender is arrested under the authority granted in subsection 1 of this section, the
27 offender shall have the right to a preliminary hearing on the violation charged unless the offender
28 waives such hearing. Upon such arrest and detention, the parole or probation officer shall
29 immediately notify the board and shall submit in writing a report showing in what manner the
30 offender has violated the conditions of his parole or conditional release. The board shall order the
31 offender discharged from such facility, require as a condition of parole or conditional release the
32 placement of the offender in a treatment center operated by the department of corrections, or shall
33 cause the offender to be brought before it for a hearing on the violation charged, under such rules and
34 regulations as the board may adopt. If the violation is established and found, the board may continue
35 or revoke the parole or conditional release, or enter such other order as it may see fit. If no violation
36 is established and found, then the parole or conditional release shall continue. If at any time during
37 release on parole or conditional release the offender is arrested for a crime which later leads to
38 conviction, and sentence is then served outside the Missouri department of corrections, the board
39 shall determine what part, if any, of the time from the date of arrest until completion of the sentence
40 imposed is counted as time served under the sentence from which the offender was paroled or
41 conditionally released.

42 3. An offender for whose return a warrant has been issued by the board shall, if it is found that
43 the warrant cannot be served, be deemed to be a fugitive from justice or to have fled from justice. If it
44 shall appear that the offender has violated the provisions and conditions of his parole or conditional
45 release, the board shall determine whether the time from the issuing date of the warrant to the date of
46 his arrest on the warrant, or continuance on parole or conditional release shall be counted as time
47 served under the sentence. In all other cases, time served on parole or conditional release shall be
48 counted as time served under the sentence.

1 4. At any time during parole or probation, the board may issue a warrant for the arrest of any
2 person from another jurisdiction, the visitation and supervision of whom the board has undertaken
3 pursuant to the provisions of the interstate compact for the supervision of parolees and probationers
4 authorized in section 217.810, for violation of any of the conditions of release, or a notice to appear
5 to answer a charge of violation. The notice shall be served personally upon the person. The warrant
6 shall authorize any law enforcement officer to return the offender to any suitable detention facility
7 designated by the board. Any parole or probation officer may arrest such person without a warrant, or
8 may deputize any other officer with power of arrest to do so by issuing a written statement setting
9 forth that the defendant has, in the judgment of the parole or probation officer, violated the
10 conditions of his release. The written statement delivered with the person by the arresting officer to
11 the official in charge of the detention facility to which the person is brought shall be sufficient legal
12 authority for detaining him. After making an arrest the parole or probation officer shall present to the
13 detaining authorities a similar statement of the circumstances of violation.

14 217.722.1. If any probation officer has probable cause to believe that the person on probation
15 has violated a condition of probation, the probation officer [may] shall issue a warrant for the arrest
16 of the person on probation. The officer may effect the arrest or may deputize any other officer with
17 the power of arrest to do so by giving the officer a copy of the warrant which will outline the
18 circumstances of the alleged violation and contain the statement that the person on probation has, in
19 the judgment of the probation officer, violated the conditions of probation. The warrant delivered
20 with the offender by the arresting officer to the official in charge of any jail or other detention
21 facility shall be sufficient authority for detaining the person on probation pending a preliminary
22 hearing on the alleged violation. Other provisions of law relating to release on bail of persons charged
23 with criminal offenses shall be applicable to persons detained on alleged probation violations.

24 2. Any person on probation arrested under the authority granted in subsection 1 of this section
25 shall have the right to a preliminary hearing on the violation charged as long as the person on
26 probation remains in custody or unless the offender waives such hearing. The person on probation
27 shall be notified immediately in writing of the alleged probation violation. If arrested in the
28 jurisdiction of the sentencing court, and the court which placed the person on probation is
29 immediately available, the preliminary hearing shall be heard by the sentencing court. Otherwise, the
30 person on probation shall be taken before a judge or associate circuit judge in the county of the
31 alleged violation or arrest having original jurisdiction to try criminal offenses or before an impartial
32 member of the staff of the Missouri board of probation and parole, and the preliminary hearing shall
33 be held as soon as possible after the arrest. Such preliminary hearings shall be conducted as provided
34 by rule of court or by rules of the Missouri board of probation and parole. If it appears that there is
35 probable cause to believe that the person on probation has violated a condition of probation, or if the
36 person on probation waives the preliminary hearing, the judge or associate circuit judge, or member
37 of the staff of the Missouri board of probation and parole shall order the person on probation held for
38 further proceedings in the sentencing court. If probable cause is not found, the court shall not be
39 barred from holding a hearing on the question of the alleged violation of a condition of probation nor
40 from ordering the person on probation to be present at such a hearing.

41 3. Upon such arrest and detention, the probation officer shall immediately notify the
42 sentencing court and shall submit to the court a written report showing in what manner the person on
43 probation has violated the conditions of probation. Thereupon, or upon arrest by warrant, the court
44 shall cause the person on probation to be brought before it without unnecessary delay for a hearing
45 on the violation charged. Revocation hearings shall be conducted as provided by rule of court.

46 306.126. 1. [The operator of a motorboat shall not allow any person to ride or sit on the
47 gunwales, decking over the bow, railing, top of seat back or decking over the back of the motorboat
48 while under way, unless such person is inboard of adequate guards or railing provided on the

1 motorboat to prevent a passenger from being lost overboard. As used in this section, the term
 2 "adequate guards or railing" means guards or railings having a height parameter of at least six inches
 3 but not more than eighteen inches. Nothing in this section shall be construed to mean that passengers
 4 or other persons aboard a motorboat cannot occupy the decking over the bow of the boat to moor it
 5 to a mooring buoy or to cast off from such a buoy, or for any other necessary purpose. The
 6 provisions of this section shall not apply to vessels propelled by sail.

7 2.] Whenever any person leaves any watercraft, other than a personal watercraft, on the
 8 waters of the Mississippi River, the waters of the Missouri River or the lakes of this state and enters
 9 the water between the hours of 11:00 a.m. and sunset, the operator of such watercraft shall display on
 10 the watercraft a red or orange flag measuring not less than twelve inches by twelve inches. The
 11 provisions of this subsection shall not apply to watercraft that is moored or anchored. The flag
 12 required by this subsection shall be visible for three hundred sixty degrees around the horizon when
 13 displayed and shall be displayed only when an occupant of the watercraft has left the confines of the
 14 watercraft and entered the water. The flag required by this subsection shall not be displayed when
 15 the watercraft is engaged in towing any person, but shall be displayed when such person has ceased
 16 being towed and has reentered the water.

17 [3.] 2. No operator shall knowingly operate any watercraft within fifty yards of a flag
 18 required by subsection 2 of this section at a speed in excess of a slow-no wake speed."; and
 19

20 Further amend said bill and page, Section 541.033, Line 16, by inserting immediately after said line
 21 the following:
 22

23 "568.068. 1. A person commits the offense of abuse of an unborn child as defined in section
 24 188.015 if such person ingests, injects, consumes, inhales, or otherwise uses a narcotic drug or a
 25 controlled substance without a prescription while such person is pregnant and such person knows or
 26 reasonably should have known that such person was pregnant.

27 2. The offense of abuse of an unborn child is:

28 (1) A class C felony if the child is born addicted to or harmed by the narcotic drug or
 29 controlled substance; or

30 (2) A class B felony if the child dies as a result of the conduct chargeable under the
 31 provisions of this section.

32 579.010. 1. A person commits the offense of ingesting a controlled substance if he or she
 33 intentionally ingests, inhales, or otherwise takes into the body any controlled substance, unless the
 34 substance was obtained directly from, or pursuant to, a valid prescription or order of a practitioner
 35 while acting in the course of a practitioner's professional practice.

36 2. The offense of ingesting a controlled substance is a Class A misdemeanor.

37 3. The venue for a violation of this section exists in either the jurisdiction in which the
 38 controlled substance was ingested, inhaled, or otherwise taken into the body or the jurisdiction in
 39 which the controlled substance was detected in the body of the accused."; and
 40

41 Further amend said bill by amending the title, enacting clause, and intersectional references
 42 accordingly.
 43